JP2022518232A5 - - Google Patents
Info
- Publication number
- JP2022518232A5 JP2022518232A5 JP2021541578A JP2021541578A JP2022518232A5 JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5 JP 2021541578 A JP2021541578 A JP 2021541578A JP 2021541578 A JP2021541578 A JP 2021541578A JP 2022518232 A5 JP2022518232 A5 JP 2022518232A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| US62/794,231 | 2019-01-18 | ||
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022518232A JP2022518232A (ja) | 2022-03-14 |
| JP2022518232A5 true JP2022518232A5 (https=) | 2023-01-27 |
| JPWO2020150639A5 JPWO2020150639A5 (https=) | 2023-01-27 |
| JP7574198B2 JP7574198B2 (ja) | 2024-10-28 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541578A Active JP7574198B2 (ja) | 2019-01-18 | 2020-01-17 | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (https=) |
| EP (1) | EP3911310A4 (https=) |
| JP (1) | JP7574198B2 (https=) |
| KR (1) | KR20210117303A (https=) |
| CN (1) | CN113438947A (https=) |
| AU (1) | AU2020208637A1 (https=) |
| BR (1) | BR112021014112A2 (https=) |
| CA (1) | CA3126822A1 (https=) |
| EA (1) | EA202191992A1 (https=) |
| IL (1) | IL284907A (https=) |
| MX (1) | MX2021008546A (https=) |
| SG (1) | SG11202107317WA (https=) |
| WO (1) | WO2020150639A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3153424A1 (en) * | 2019-10-03 | 2021-04-08 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| JP7846686B2 (ja) * | 2020-10-02 | 2026-04-15 | ドラセン ファーマシューティカルズ インコーポレイテッド | 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用 |
| EP4229029B1 (en) * | 2020-10-15 | 2026-02-25 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| CN114621120B (zh) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | 一种don前药分子、前药激活化合物和前药激活体系 |
| US20240246902A1 (en) * | 2021-04-29 | 2024-07-25 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| EP3113798B1 (en) | 2014-03-07 | 2019-06-05 | University Health Network | Methods and compositions for modifying the immune response |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| CA2994165A1 (en) | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods for cancer and immunotherapy using glutamine analogues, including don |
| EP3328374A4 (en) | 2015-07-31 | 2019-03-13 | The Johns Hopkins University | GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES |
| AU2016302940B2 (en) | 2015-07-31 | 2021-02-04 | The Johns Hopkins University | Prodrugs of glutamine analogs |
| US20180244783A1 (en) * | 2015-08-31 | 2018-08-30 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN110869765A (zh) * | 2017-04-20 | 2020-03-06 | Adc治疗有限公司 | 组合疗法 |
| CN111566083A (zh) * | 2017-10-06 | 2020-08-21 | 约翰·霍普金斯大学 | 新的谷氨酰胺拮抗剂及其用途 |
-
2020
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 EA EA202191992A patent/EA202191992A1/ru unknown
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/zh active Pending
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/ko not_active Ceased
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/pt not_active IP Right Cessation
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en not_active Abandoned
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en not_active Withdrawn
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en not_active Ceased
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/es unknown
- 2020-01-17 JP JP2021541578A patent/JP7574198B2/ja active Active
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown